ChemicalBook > Product Catalog >API >Circulatory system drugs >Antiarrhythmics Drugs >DISOPYRAMIDE

DISOPYRAMIDE

DISOPYRAMIDE Suppliers list
Company Name: Mainchem Co., Ltd.
Tel: +86-0592-6210733
Email: sales@mainchem.com
Products Intro: Product Name:DISOPYRAMIDE
CAS:3737-09-5
Company Name: J & K SCIENTIFIC LTD.  
Tel: 400-666-7788 +86-10-82848833
Email: jkinfo@jkchemical.com;market6@jkchemical.com
Products Intro: Product Name:DisopyraMide
CAS:3737-09-5
Package:100Mg,1g
Company Name: 3B Pharmachem (Wuhan) International Co.,Ltd.  
Tel: 86-21-50328103 * 801、802、803、804 Mobile:18930552037
Email: 3bsc@sina.com
Products Intro: Product Name:DISOPYRAMIDE
CAS:3737-09-5
Purity:99% HPLC Package:1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;10g
Company Name: TCI (Shanghai) Development Co., Ltd.  
Tel: 021-67121386 / 800-988-0390
Email: Sales-CN@TCIchemicals.com
Products Intro: Product Name:Disopyramide
CAS:3737-09-5
Purity:98.0% LC&T Package:1G,5G
Company Name: Chemsky(shanghai)International Co.,Ltd.  
Tel: 021-50135380
Email: shchemsky@sina.com
Products Intro: Product Name:DisopyraMide
CAS:3737-09-5
Purity:98%
DISOPYRAMIDE Basic information
Product Name:DISOPYRAMIDE
Synonyms:ALPHA-[2-[BIS(1-METHYLETHYL)AMINO]ETHYL]-ALPHA-PHENYL-2-PYRIDINE ACETAMIDE;ALPHA-DIISOPROPYLAMINOETHYL-ALPHA-PHENYLPYRIDINE-2-ACETAMIDE;DISOPYRAMIDE;2-Pyridineacetamide, alpha-[2-(diisopropylamino)ethyl]-alpha-phenyl-;2-Pyridineacetamide, alpha-[2-[bis(1-methylethyl)amino]ethyl]-alpha-phenyl-;4-(Diisopropylamino)-2-phenyl-2-(2-pyridinyl)butanamide;4-Diisopropylamino-2-phenyl-2-(2-pyridyl)-butyramide;alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamid
CAS:3737-09-5
MF:C21H29N3O
MW:339.47
EINECS:223-110-2
Product Categories:Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:3737-09-5.mol
DISOPYRAMIDE Structure
DISOPYRAMIDE Chemical Properties
Melting point 94.5-950C
Boiling point 475.43°C (rough estimate)
density 1.0779 (rough estimate)
refractive index 1.6300 (estimate)
storage temp. 2-8°C
pka10.2; also reported as 10.45(at 25℃)
Merck 14,3360
CAS DataBase Reference3737-09-5(CAS DataBase Reference)
Safety Information
Hazard Codes Xn,Xi,T,F
Risk Statements 22-36/37/38-39/23/24/25-23/24/25-11
Safety Statements 36-26-45-36/37-16-7
WGK Germany 3
RTECS UR8432000
ToxicityLD50 i.p. in mice: 517 mmol/kg (Ruenitz, Mokler)
MSDS Information
ProviderLanguage
SigmaAldrich English
DISOPYRAMIDE Usage And Synthesis
Chemical PropertiesCrystalline Solid
UsesAntiarrhythmic (class IA). Sodium channel blocker
UsesAntiarrhythmic;Na+ channel blocker
DefinitionChEBI: A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.
Brand nameNorpace (Searle).
Clinical UseDisopyramide (Norpace) can suppress atrial and ventricular arrhythmias and is longer acting than other drugs in its class.
The indications for use of disopyramide are similar to those for quinidine, except that it is not approved for use in the prophylaxis of atrial flutter or atrial fibrillation after DC conversion.The indications are as follows: unifocal premature (ectopic) ventricular contractions, premature (ectopic) ventricular contractions of multifocal origin, paired premature ventricular contractions (couplets), and episodes of ventricular tachycardia. Persistent ventricular tachycardia is usually treated with DC conversion.
Side effectsThe major toxic reactions to disopyramide administration include hypotension, congestive heart failure, and conduction disturbances. These effects are the result of disopyramide’s ability to depress myocardial contractility and myocardial conduction. Although disopyramide initially may produce ventricular tachyarrhythmias or ventricular fibrillation in some patients, the incidence of disopyramide-induced syncope in long-term therapy is not known. Most other toxic reactions (e.g., dry mouth, blurred vision, constipation) can be attributed to the anticholinergic properties of the drug.
CNS stimulation and hallucinations are rare.The incidence of severe adverse effects in long-term therapy may be lower than those observed with quinidine or procainamide.
Drug interactionsIn the presence of phenytoin, the metabolism of disopyramide is increased (reducing its effective concentration) and the accumulation of its metabolites is also increased, thereby increasing the probability of anticholinergic adverse effects. Rifampin also stimulates the hepatic metabolism of disopyramide, reducing its plasma concentration.
Unlike quinidine, disopyramide does not increase the plasma concentration of digoxin in patients receiving a maintenance dose of the cardiac glycoside. Hypoglycemia has been reported with the use of disopyramide, particularly in conjunction with moderate or excessive alcohol intake.
PrecautionsDisopyramide should not be administered in cardiogenic shock, preexisting second- or third-degree A-V block, or known hypersensitivity to the drug. Neither should it be given to patients who are poorly compensated or those with uncompensated heart failure or severe hypotension. Because of its ability to slow cardiac conduction, disopyramide is not indicated for the treatment of digitalis-induced ventricular arrhythmias.
Patients with congenital prolongation of the QT interval should not receive quinidine, procainamide, or disopyramide because further prolongation of the QT interval may increase the incidence of ventricular fibrillation. Because of its anticholinergic properties, disopyramide should not be used in patients with glaucoma. Urinary retention and benign prostatic hypertrophy are also relative contraindications to disopyramide therapy. Patients with myasthenia gravis may have a myasthenic crisis after disopyramide administration as a result of the drug’s local anesthetic action at the neuromuscular junction.The elderly patient may exhibit increased sensitivity to the anticholinergic actions of disopyramide. Caution is advised when disopyramide is used in conjunction with other cardiac depressant drugs, such as verapamil, which may adversely affect atrioventricular conduction.
DISOPYRAMIDE Preparation Products And Raw materials
Raw materialsBenzeneacetonitrile-->2-Chloropropane-->2-Bromopyridine
Tag:DISOPYRAMIDE(3737-09-5) Related Product Information
1-(2,6-Dimethylphenoxy)-2-propanamine Desisopropyl Disopyramide-D7 Oxalate Disopyramide-d14 Tosylate Salt (-)-(R)-Disopyramide,(R)-(-)-Disopyramide,(R)-Disopyramide,l-Disopyramide Disopyramide Base (S)-(+)-Disopyramide,(S)-Disopyramide,d-Disopyramide,(+)-(S)-Disopyramide Desisopropyl Disopyramide Oxalate DISOPYRAMIDE PHOSPHATE,DISOPYRAMIDE PHOSPHATE SALT Phenyl-(2-pyridyl)acetamide alpha-Methylhydratropamide PYRIDINE-2-ACETAMIDE 3-(2-PYRIDINYL)PROPYLAMINE N,N,3,3-Tetramethylbutylamine, 99% 2-ISOPROPYL PYRIDINE Mono-isopropyl-disopyramide 2-PHENYLBUTYRAMIDE 2-Pyridylethylamine 2-TERT-BUTYLPYRIDINE